Calviri’s Immunosignature (IMS) Technology is universally applicable to the development of diagnostic products. It is based on the recognition that combinatorial peptide sequences provide a richer source of possible antibody binding ligands than proteomic sequences, which are highly redundant. The diversity of antibody specificities is far greater than the diversity of proteomes. The IMS Technology enables an individual’s immense antibody repertoire to be broadly queried and reproducibly measured.

Our IMS approach rests on three key principles:

  • IMS engages the full antibody repertoire as disease-induced biomarkers.
  • The combinatorially-designed ligands represent a library of mimetic variants of the original epitopes that elicited the antibodies.
  • Competitive, parallel binding of antibodies to the library of IMS peptides maximizes the resolution of antibody specificities.

An immunosignature assay provides individual readouts of the many components of a person’s antibody response. This contrasts with a conventional enzyme-linked immunosorbent assay (ELISA) in which all the binding events to the whole virus or antigen in an assay-well are summed into a single readout.


Antibodies are Disease-Amplified Biomarkers

  • Our immune system is a whole-body surveillance network which  is alerted by an antigen from infection or bad cells.
  • Alerted B-cells of the immune system secrete antibodies that recognize the infection or bad cells.
  • Immunosignatures use the specificities of the proliferating antibodies to define health states.

Libraries of High-diversity Peptides Sample Combinatorially possible Sequences

  • Proteomic sequence space is highly redundant.
  • The amino acid sequence strings comprising proteomes correspond to a very small proportion of all possible combinations.
  • Peptides can be selected to evenly sample combinatorial sequence space.

In an IMS Immunoassay, Arrayed Libraries of Diverse Peptides Serve as Mimotopes of Antibody-Ligands

  • The diverse peptides selected from combinatorial space serve as ligand mimotopes which are recognized by antibodies.
  • The workflow of an IMS immunoassay resembles that of an ELISA
  • An IMS assay results in a large dataset of quantified measurements.

An IMS Assay Provides 100s of Thousands of Simultaneous Immune Measurements, Which Enable More Complex Biological Insights

  • In an ELISA, an antibody containing sample, such as serum, is mixed with antigen in a microtiter plate well. All antibody species are exposed to the same antigenic material.
  • Even if multiple antibodies bind, only one measurement can be readout, representing the sum of events.
ELISA_graphic copyv2
  • In an IMS assay, an antibody containing sample is applied to arrays and addressable ligands physically fixed to the surface. The repertoire of antibodies in the sample simultaneously and competitively query >105 possible interactions.
  • Each antibody species that binds to any peptide sequence is individually detected and quantitatively measured.


Diagnostic tests for many different diseases can be developed with Calviri’s IMS technology. Many published studies have demonstrated the breadth of its application to distinguishing either chronic or infectious diseases from non-disease states. In particular, we have demonstrated its utility for diagnosing cancer from non-cancer, distinguishing different cancers or differential diagnoses. The IMS approach can be used independently or in combination with the FSP technology.